Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 67

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1‐PRKACA fusion

Graham, Rondell P., Lackner, Carolin, Terracciano, Luigi, González‐Cantú, Yessica, Maleszewski, Joseph J., Greipp, Patricia T., Simon, Sanford M., Torbenson, Michael S. · 2018 · Hepatology

Abstract

Fibrolamellar carcinomas are characterized by activation of protein kinase A, a kinase composed of catalytic and regulatory subunits. PRKACA encodes a catalytic subunit of protein kinase A, and almost all fibrolamellar carcinomas have a heterozygous 400‐kb deletion that leads to the fusion of DNAJB1 and PRKACA . The resulting DNAJB1‐PRKACA fusion transcript is believed to activate protein kinase A by dysregulation of the catalytic portion of the protein. In contrast, PRKAR1A encodes one of the regulatory subunits of protein kinase A. We hypothesized that loss of function of this regulatory unit could also lead to protein kinase A activation and thus to fibrolamellar carcinoma. Because PRKAR1A mutations underlie the Carney complex, we searched for liver tumors in individuals with the Carney complex. We identified 3 individuals with fibrolamellar carcinomas and a personal history of the Carney complex. All three tumors displayed the typical morphology of fibrolamellar carcinoma and were positive for arginase, cytokeratin 7, and cluster of differentiation 68. Fluorescence in situ hybridization was negative for PRKACA rearrangements. However, PRKAR1A sequencing identified pathogenic mutations in two of two cases with successful sequencing. In addition, all three cases were negative for PRKAR1A protein expression, consistent with inactivation of this key regulatory unit of protein kinase A. We also identified one additional fibrolamellar carcinoma in an individual without a documented history of the Carney complex who was negative for PRKACA rearrangements but had loss of PRKAR1A protein expression as well as PRKAR1A mutations. Conclusion : Fibrolamellar carcinoma can be part of the Carney complex; in this setting, fibrolamellar carcinomas have inactivating PRKAR1A mutations instead of the DNAJB1‐PRKACA fusion gene found in sporadic fibrolamellar carcinomas, providing an alternate means for activation of protein kinase A. (H epatology 2017).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.29719

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 22

  1. 2017, Fibrolamellar carcinoma: a histologically unique tumor with unique molecular findings, Semin Diagn Pathol, 34, 146, 10.1053/j.semdp.2016.12.010 · DOI
  2. 1980, Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico‐pathologic features, Cancer, 46, 372, 10.1002/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S · doi:10.1002/1097-0142(19800715)46:2<372::aid-cncr2820460227>3.0.co;2-s
  3. 2011, Fibrolamellar carcinomas are positive for CD68, Mod Pathol, 24, 390, 10.1038/modpathol.2010.207 · doi:10.1038/modpathol.2010.207
  4. 2014, Detection of a recurrent DNAJB1‐PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma, Science, 343, 1010, 10.1126/science.1249484 · DOI · Paper page
  5. 2015, DNAJB1‐PRKACA is specific for fibrolamellar carcinoma, Mod Pathol, 28, 822, 10.1038/modpathol.2015.4 · DOI · Paper page
  6. 2015, Transcriptomic characterization of fibrolamellar hepatocellular carcinoma, Proc Natl Acad Sci USA, 112, E5916
  7. 2017, Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non‐coding RNA signature of fibrolamellar carcinoma, Sci Rep, 7, 44653, 10.1038/srep44653 · DOI
  8. 2016, Protein kinase A catalytic subunit isoform PRKACA; history, function and physiology, Gene, 577, 101, 10.1016/j.gene.2015.11.052 · DOI · Paper page
  9. 1974, Activation of protein kinase by physiological concentrations of cyclic AMP, Proc Natl Acad Sci USA, 71, 3580, 10.1073/pnas.71.9.3580 · DOI · Paper page
  10. 1985, The complex of myxomas, spotty pigmentation, and endocrine overactivity, Medicine (Baltimore), 64, 270, 10.1097/00005792-198507000-00007 · DOI · Paper page
  11. 2017, Molecular testing for the clinical diagnosis of fibrolamellar carcinoma, Mod Pathol
  12. 2004, Fibrolamellar hepatocellular carcinoma occurring 5 years after hepatocellular adenoma in a 14‐year‐old girl: a case report with comparative genomic hybridization analysis, Arch Pathol Lab Med, 128, 222, 10.5858/2004-128-222-FHCOYA · doi:10.5858/2004-128-222-fhcoya
  13. 2016, Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss, Mod Pathol, 29, 607, 10.1038/modpathol.2016.59 · DOI
  14. 2015, Synchronous fibrolamellar hepatocellular carcinoma and auricular myxoma, Case Rep Pathol, 2015, 241708
  15. 2015, Primary hepatic tumors with myxoid change: morphologically unique hepatic adenomas and hepatocellular carcinomas, Am J Surg Pathol, 39, 318, 10.1097/PAS.0000000000000382 · DOI
  16. 1987, Adrenocortical micronodular dysplasia, cardiac myxomas, lentigines, and spindle cell tumors. Report of a kindred, Arch Intern Med, 147, 443, 10.1001/archinte.1987.00370030047011 · DOI
  17. 1987, The complex of myxomas, spotty pigmentation, and endocrine overactivity, Arch Intern Med, 147, 418, 10.1001/archinte.1987.00370030022003 · doi:10.1001/archinte.1987.00370030022003
  18. 2008, A novel PRKAR1A mutation associated with hepatocellular carcinoma in a young patient and a variable Carney complex phenotype in affected subjects in older generations, Clin Endocrinol (Oxf), 69, 751, 10.1111/j.1365-2265.2008.03286.x · DOI
  19. 2001, Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation, J Clin Endocrinol Metab, 86, 4041, 10.1210/jcem.86.9.7903 · doi:10.1210/jcem.86.9.7903 · Paper page
  20. 2004, Comparative PRKAR1A genotype–phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice, Proc Natl Acad Sci USA, 101, 14222, 10.1073/pnas.0405535101 · DOI
  21. 2016, FGFR1 and FGFR2 in fibrolamellar carcinoma, Histopathology, 68, 686, 10.1111/his.12799 · doi:10.1111/his.12799
  22. 2014, PRKAR1A in the development of cardiac myxoma: a study of 110 cases including isolated and syndromic tumors, Am J Surg Pathol, 38, 1079, 10.1097/PAS.0000000000000202 · DOI

Cited by

See all 67

Metadata

Authors
Graham, R. P., Lackner, C., Terracciano, L., González‐Cantú, Y., Maleszewski, J. J., Greipp, P. T., Simon, S. M., & Torbenson, M. S.
Venue
Hepatology
Published
2018-05-11
Volume
68
Issue
4
Pages
1441-1447
ISSN
  • 0270-9139
  • 1527-3350
Cited by
67
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1‐PRKACA fusion. https://app.cochat.ai/papers/10.1002/hep.29719
The paper
Graham, R. P., Lackner, C., Terracciano, L., González‐Cantú, Y., Maleszewski, J. J., Greipp, P. T., Simon, S. M., & Torbenson, M. S. (2018). Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1‐PRKACA fusion. Hepatology. https://doi.org/10.1002/hep.29719

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.